396 related articles for article (PubMed ID: 23314196)
1. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
Duarte AI; Candeias E; Correia SC; Santos RX; Carvalho C; Cardoso S; Plácido A; Santos MS; Oliveira CR; Moreira PI
Biochim Biophys Acta; 2013 Apr; 1832(4):527-41. PubMed ID: 23314196
[TBL] [Abstract][Full Text] [Related]
2. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
García-Casares N; García-Arnés JA; Gómez-Huelgas R; Valdivielso-Felices P; García-Arias C; González-Santos P
Rev Neurol; 2014 Dec; 59(11):517-24. PubMed ID: 25418147
[TBL] [Abstract][Full Text] [Related]
3. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes.
Xu W; Yang Y; Yuan G; Zhu W; Ma D; Hu S
J Investig Med; 2015 Feb; 63(2):267-72. PubMed ID: 25479064
[TBL] [Abstract][Full Text] [Related]
4. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.
Candeias E; Sebastião I; Cardoso S; Carvalho C; Santos MS; Oliveira CR; Moreira PI; Duarte AI
Mol Neurobiol; 2018 May; 55(5):4030-4050. PubMed ID: 28573460
[TBL] [Abstract][Full Text] [Related]
5. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
6. Liraglutide Protects Against Brain Amyloid-β
Duarte AI; Candeias E; Alves IN; Mena D; Silva DF; Machado NJ; Campos EJ; Santos MS; Oliveira CR; Moreira PI
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32143329
[TBL] [Abstract][Full Text] [Related]
7. Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide.
Candeias EM; Sebastião IC; Cardoso SM; Correia SC; Carvalho CI; Plácido AI; Santos MS; Oliveira CR; Moreira PI; Duarte AI
World J Diabetes; 2015 Jun; 6(6):807-27. PubMed ID: 26131323
[TBL] [Abstract][Full Text] [Related]
8. Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes.
Ross SA; Ballantine J
Curr Med Res Opin; 2013 Dec; 29(12):1617-26. PubMed ID: 23971789
[TBL] [Abstract][Full Text] [Related]
9. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
10. Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology.
Candeias E; Duarte AI; Sebastião I; Fernandes MA; Plácido AI; Carvalho C; Correia S; Santos RX; Seiça R; Santos MS; Oliveira CR; Moreira PI
Mol Neurobiol; 2017 Oct; 54(8):6471-6489. PubMed ID: 27730513
[TBL] [Abstract][Full Text] [Related]
11. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
12. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?
Li L
Neurosci Bull; 2007 Jan; 23(1):58-65. PubMed ID: 17592527
[TBL] [Abstract][Full Text] [Related]
13. Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus.
Siddiqui NI
Mymensingh Med J; 2009 Jan; 18(1):113-24. PubMed ID: 19182763
[TBL] [Abstract][Full Text] [Related]
14. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
McClean PL; Hölscher C
Neuropharmacology; 2014 Jan; 76 Pt A():57-67. PubMed ID: 23973293
[TBL] [Abstract][Full Text] [Related]
15. Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.
Hölscher C
J Endocrinol; 2014 Apr; 221(1):T31-41. PubMed ID: 23999914
[TBL] [Abstract][Full Text] [Related]
16. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
McClean PL; Gault VA; Harriott P; Hölscher C
Eur J Pharmacol; 2010 Mar; 630(1-3):158-62. PubMed ID: 20035739
[TBL] [Abstract][Full Text] [Related]
18. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
Bak AM; Egefjord L; Gejl M; Steffensen C; Stecher CW; Smidt K; Brock B; Rungby J
Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
[TBL] [Abstract][Full Text] [Related]
19. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
Calsolaro V; Edison P
CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230
[TBL] [Abstract][Full Text] [Related]
20. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
Nowell J; Blunt E; Gupta D; Edison P
Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
